Skip to main content

Kresmion event archive

130 cross-asset events fired across commodity, crypto, equity, forex, macro. See also the Kresmion brief for 2026-06-17.

commodity (18)

  • highWeather supply riskCL=F

    Texas Permian Basin: drought conditions detected - potential oil supply impact

  • highOSINT energyOIL

    OSINT: US S&P 500 Index Slides 5%

  • highFutures price gapCT=F

    Cotton bull 6.3% vs prior close ($75.01 → $79.73)

  • highFutures volume spikePL=F

    Platinum volume spike - 2.4× the 20-day average (31 vs 12 avg)

  • highOSINT energyOIL

    OSINT: US Oil Market Alert Signals Potential Supply Shift

  • highOSINT energyOIL

    OSINT: US and Iran Seal Agreement at Bürgenstock, Switzerland

  • highOSINT energyOIL

    OSINT: China Deploys New 155mm Naval Gun, Boosting Firepower Near Taiwan

  • highCommodityOIL

    Oil -6.69% - significant selloff

  • mediumFutures price gapZW=F

    Wheat bull 4.3% vs prior close ($596.00 → $621.50)

  • mediumFutures price gapPL=F

    Platinum bear 4.1% vs prior close ($1,812.10 → $1,738.30)

  • mediumCommodityGOLD

    Gold -1.12% - significant selloff

  • mediumCommodityOIL

    Oil -1.13% - significant selloff

  • mediumCommodityGOLD

    Gold +1.11% - significant rally

  • mediumCommodityOIL

    Oil +1.12% - significant rally

  • mediumCommodityOIL

    Oil -1.12% - significant selloff

  • mediumOSINT eventOIL

    OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

  • mediumOSINT eventOIL

    OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

  • lowFutures price gapSB=F

    Sugar No. 11 bull 4.0% vs prior close ($13.82 → $14.37)

crypto (20)

  • highETF flowETH

    ETH ETF inflow of $139M - institutional buying

  • highETF flowBTC

    BTC ETF inflow of $1031M - institutional buying

  • highOpen interestBTC

    BTC open interest +248.9% - OI surge

  • highOpen interestSOL

    SOL open interest -62.5% - OI collapse

  • highOpen interestETH

    ETH open interest +225.5% - OI surge

  • highOpen interestETH

    ETH open interest -67.9% - OI collapse

  • highOpen interestSOL

    SOL open interest -34.4% - OI collapse

  • highOpen interestBTC

    BTC open interest +67.0% - OI surge

  • highOpen interestBTC

    BTC open interest +102.6% - OI surge

  • highOpen interestETH

    ETH open interest -68.9% - OI collapse

  • highOpen interestSOL

    SOL open interest -33.1% - OI collapse

  • highDEX thin liquiditySPYx

    SPYx/USDC has $67.6M volume but only $748K liquidity - thin market, slippage risk

  • highOpen interestETH

    ETH open interest -66.8% - OI collapse

  • highOpen interestBTC

    BTC open interest -40.7% - OI collapse

  • highOpen interestSOL

    SOL open interest -32.3% - OI collapse

  • mediumOSINT eventCRYPTO

    OSINT: Large $HYPE Withdrawal by Wallet 0x6436 Sparks Sell Pressure

  • mediumOSINT eventCRYPTO

    OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

  • mediumOSINT eventCRYPTO

    OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

  • mediumOSINT eventCRYPTO

    OSINT: On-chain products poised for mainstream app integration amid clearer regs

  • mediumOSINT eventCRYPTO

    OSINT: Whale bets $1.8M against Argentina in World Cup opener

equity (78)

  • highClinical trial terminatedJNJ

    Phase 3 trial terminated early - JOHNSON MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Au

  • highClinical trial terminatedJNJ

    Phase 3 trial terminated early - JOHNSON Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

  • highClinical trial terminatedJNJ

    Phase 3 trial terminated early - JOHNSON The Duration Study

  • highClinical trial terminatedLLY

    Phase 3 trial terminated early - ELI Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adul

  • highClinical trial terminatedBMY

    Phase 3 trial terminated early - BRISTOL A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone i

  • highClinical trial terminatedBMY

    Phase 3 trial terminated early - BRISTOL Apixaban in Patients With Sickle Cell Disease

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progressi

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta

  • highClinical trial terminatedAMGN

    Phase 3 trial terminated early - AMGEN Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adul

  • highClinical trial terminatedINCY

    Phase 3 trial terminated early - INCYTE A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

  • highClinical trial terminatedREGN

    Phase 3 trial terminated early - REGENERON Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia

  • highClinical trial terminatedMDT

    Phase 3 trial terminated early - Medtronic Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventr

  • highClinical trial terminatedMDT

    Phase 3 trial terminated early - Medtronic Ligasure II: Standard Stapling Versus Ligasure

  • highClinical trial terminatedABBV

    Phase 3 trial terminated early - AbbVie UNITE Study: Understanding New Interventions With GBM ThErapy

  • highClinical trial terminatedABBV

    Phase 3 trial terminated early - AbbVie A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endomet

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck LARC Forward Contraceptive Counseling at MHCC

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dim

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheime

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Para

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheum

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Car

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effect

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD Virtual PrEP: Rendering PrEP Delivery More Efficient

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropa

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

  • highActivist stakeLPRO

    Activist 13D filing - tender offer

  • mediumOSINT eventTECH

    OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

  • mediumTrend spikeSNY

    Sanofi search volume spiked +77 pts - unusual interest

  • mediumTrend spikeKLAC

    KLA CORP search volume spiked +39 pts - unusual interest

  • mediumEarnings below estimatesXXII

    Missed consensus by 322.0% - EPS $-361.6 vs $-85.68 estimate

  • mediumEarnings above estimatesXXII

    Beat consensus by 98.8% - EPS $-1.8 vs $-149.94 estimate

  • mediumEarnings below estimatesXXII

    Missed consensus by 114.9% - EPS $-4083 vs $-1900.26 estimate

  • mediumEarnings below estimatesXXII

    Missed consensus by 42.4% - EPS $-318 vs $-223.38 estimate

  • mediumEarnings above estimatesVRNO

    Beat consensus by 6.2% - EPS $-0.25 vs $-0.2664 estimate

  • mediumEarnings below estimatesVRNO

    Missed consensus by 347.3% - EPS $-1.35 vs $-0.3018 estimate

  • mediumEarnings below estimatesVRNO

    Missed consensus by 175.4% - EPS $-0.6 vs $-0.2179 estimate

  • mediumEarnings above estimatesSLXN

    Beat consensus by 17.0% - EPS $-28.8 vs $-34.68 estimate

  • mediumEarnings below estimatesSLXN

    Missed consensus by 17.6% - EPS $-43.2 vs $-36.72 estimate

  • mediumEarnings below estimatesPW

    Missed consensus by 23.0% - EPS $2.3 vs $2.987 estimate

  • mediumEarnings below estimatesPW

    Missed consensus by 19.7% - EPS $2.48 vs $3.09 estimate

  • mediumEarnings below estimatesLODE

    Missed consensus by 73.8% - EPS $-0.26 vs $-0.1496 estimate

  • mediumEarnings above estimatesLODE

    Beat consensus by 8.7% - EPS $-0.163 vs $-0.1785 estimate

  • mediumEarnings above estimatesKMX

    Q1-2027: Beat consensus by 35.9% - EPS $1.31 vs $0.9638 estimate

  • mediumEarnings above estimatesKMRRF

    Q1-2026: Beat consensus by 202.0% - EPS $1.91 vs $0.6324 estimate

  • mediumEarnings above estimatesKLRA

    Q1-2026: Beat consensus by 7.3% - EPS $-0.638 vs $-0.6885 estimate

  • mediumEarnings above estimatesKLAR

    Beat consensus by 94.7% - EPS $-0.01 vs $-0.1877 estimate

  • mediumEarnings above estimatesKLAC

    Beat consensus by 7.4% - EPS $0.938 vs $0.873 estimate

  • mediumEarnings above estimatesINR

    Beat consensus by 273.7% - EPS $3.43 vs $0.9178 estimate

  • mediumEarnings above estimatesGLOO

    Q1-2027: Beat consensus by 6.4% - EPS $-0.21 vs $-0.2244 estimate

  • mediumEarnings above estimatesESOA

    Q2-2026: Beat consensus by 106.1% - EPS $0.01 vs $-0.1632 estimate

  • mediumEarnings above estimatesDRVN

    Q1-2026: Beat consensus by 19.2% - EPS $0.3 vs $0.2516 estimate

  • mediumEarnings above estimatesCREG

    Beat consensus by 24.8% - EPS $700 vs $561 estimate

  • mediumEarnings above estimatesCREG

    Beat consensus by 74.3% - EPS $1600 vs $918 estimate

  • mediumEarnings above estimatesCDLX

    Beat consensus by 49.4% - EPS $-1.1 vs $-2.176 estimate

  • mediumEarnings above estimatesCDLX

    Beat consensus by 142.0% - EPS $0.3 vs $-0.714 estimate

  • mediumTrend spikeGEV

    GE Vernova Inc. search volume spiked +100 pts - unusual interest

  • mediumTrend spikeLIN

    LINDE PLC search volume spiked +100 pts - unusual interest

  • mediumTrend spikeISRG

    INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

  • mediumEarnings below estimatesPDCC

    Q1-2026: Missed consensus by 34.6% - EPS $0.31 vs $0.4743 estimate

  • mediumEarnings above estimatesDOMO

    Q1-2027: Beat consensus by 70.3% - EPS $-0.02 vs $-0.0673 estimate

  • mediumOSINT eventTECH

    OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

  • mediumTrend spikeMSTR

    Strategy Inc search volume spiked +26 pts - unusual interest

  • mediumOSINT eventTECH

    OSINT: On-chain products poised for mainstream app integration amid clearer regs

  • lowEarnings above estimatesVQSSF

    Q1-2026: EPS $0.002 vs $-0.0103 estimate, +0.01 on a near-zero consensus

  • lowEarnings above estimatesTTRX

    Q4-2025: EPS $0.01 vs $-0.0408 estimate, +0.05 on a near-zero consensus

  • lowEarnings above estimatesSMDRF

    Q4-2025: EPS $0.07 vs $0.0281 estimate, +0.04 on a near-zero consensus

  • lowEarnings below estimatesPBSV

    Q2-2026: EPS $0.01 vs $0.0306 estimate, -0.02 on a near-zero consensus

  • lowEarnings above estimatesNAVN

    EPS $0.08 vs $-0.0092 estimate, +0.09 on a near-zero consensus

  • lowEarnings below estimatesMGMNF

    Q1-2026: EPS $-0.03 vs $0.0051 estimate, -0.04 on a near-zero consensus

  • lowEarnings above estimatesHITI

    Q2-2026: EPS $0.01 vs $-0.0278 estimate, +0.04 on a near-zero consensus

forex (9)

  • mediumOSINT eventFOREX

    OSINT: US Housing Starts Plunge 15.4% MoM in May, Lowest Since 2020

  • mediumRSI level crossedDXY

    DXY RSI 71.8 - overbought (crossed above 70)

  • mediumDollar index moveDXY

    DXY +0.46% - dollar strength signal

  • mediumOSINT eventFOREX

    OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

  • mediumOSINT eventFOREX

    OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

  • mediumOSINT eventFOREX

    OSINT: Hegseth's actions spark US ally backlash over renaming initiatives

  • mediumOSINT eventFOREX

    OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

  • mediumOSINT eventFOREX

    OSINT: Whale bets $1.8M against Argentina in World Cup opener

  • mediumOSINT eventFOREX

    OSINT: US Median Home Price Hits $395K in May, Highest in Years

macro (5)

  • mediumOSINT eventDEFENSE

    OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

  • mediumVIXVIX

    VIX at 18.4 - CAUTION territory

  • mediumOSINT eventDEFENSE

    OSINT: Hegseth's actions spark US ally backlash over renaming initiatives

  • mediumOSINT eventDEFENSE

    OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

  • mediumNFCI reliefMARKET

    Financial conditions loosening - NFCI at -0.51, liquidity supportive